Melanoma protective antitumor immunity activated by catalytic DNA.

Autor: Cai H; Vascular Biology and Translational Research, School of Medical Sciences & UNSW Medicine, The University of New South Wales, Sydney, NSW, 2052, Australia., Cho EA; Dermatology Research Laboratories and Bosch Institute, The University of Sydney, Sydney, NSW, 2006, Australia., Li Y; Vascular Biology and Translational Research, School of Medical Sciences & UNSW Medicine, The University of New South Wales, Sydney, NSW, 2052, Australia., Sockler J; Statistical Operations and Programming, Datapharm Australia, Sydney, NSW, 2047, Australia., Parish CR; Cancer and Vascular Biology Group, The John Curtin School of Medical Research, The Australian National University, Building 131, Garran Rd, Acton, Canberra, ACT, 2601, Australia., Chong BH; St George Clinical School, University of New South Wales, Kogarah, NSW, 2217, Australia.; Department of Haematology, St George Hospital, Kogarah, NSW, 2217, Australia., Edwards J; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2050, Australia., Dodds TJ; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2050, Australia., Ferguson PM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2050, Australia., Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2050, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2050, Australia., Halliday GM; Dermatology Research Laboratories and Bosch Institute, The University of Sydney, Sydney, NSW, 2006, Australia., Khachigian LM; Vascular Biology and Translational Research, School of Medical Sciences & UNSW Medicine, The University of New South Wales, Sydney, NSW, 2052, Australia. L.Khachigian@unsw.edu.au.
Jazyk: angličtina
Zdroj: Oncogene [Oncogene] 2018 Sep; Vol. 37 (37), pp. 5115-5126. Date of Electronic Publication: 2018 May 29.
DOI: 10.1038/s41388-018-0306-0
Abstrakt: Melanoma incidence is increasing worldwide, and although drugs such as BRAF/MEK small-molecule inhibitors and immune checkpoint antibodies improve patient outcomes, most patients ultimately fail these therapies and alternative treatment strategies are urgently needed. DNAzymes have recently undergone clinical trials with signs of efficacy and no serious adverse events attributable to the DNAzyme. Here we investigated c-Jun expression in human primary and metastatic melanoma. We also explored the role of T cell immunity in DNAzyme inhibition of primary melanoma growth and the prevention of growth in non-treated tumors after the cessation of treatment in a mouse model. c-Jun was expressed in 80% of melanoma cells in human primary melanomas (n = 17) and in 83% of metastatic melanoma cells (n = 38). In contrast, c-Jun was expressed in only 11% of melanocytes in benign nevi (n = 24). Dz13, a DNAzyme targeting c-Jun/AP-1, suppressed both Dz13-injected and untreated B16F10 melanoma growth in the same mice, an abscopal effect relieved in each case by administration of anti-CD4/anti-CD8 antibodies. Dz13 increased levels of cleaved caspase-3 within the tumors. New, untreated melanomas grew poorly in mice previously treated with Dz13. Administration of anti-CD4/anti-CD8 antibodies ablated this inhibitory effect and the tumors grew rapidly. Dz13 inhibited c-Jun expression, reduced intratumoral vascularity (vascular lumina area defined by CD31 staining), and increased CD4 + cells within the tumors. This study provides the first demonstration of an abscopal effect of a DNAzyme on tumor growth and shows that Dz13 treatment prevents growth of subsequent new tumors in the same animal. Dz13 may be useful clinically as a therapeutic antitumor agent by preventing tumor relapse through adaptive immunity.
Databáze: MEDLINE
Externí odkaz: